Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 杨明明教授 (肿瘤学系) |
| 陈永鸿教授 (病理解剖及细胞学系) |
| 陈林教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1517/14728222.2015.1031109 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/1WOS source URL
其它资讯
摘要Introduction: Following the approval of sorafenib as the first systemic agent. for treatment of advanced hepatocellular carcinoma (HCC), there have been an increasing number of targeted treatments under testing for the cancer. However, most of the recently published drug trials in HCC failed to produce remarkable results. The researchers are actively pursuing novel therapeutic targets as well as predictive biomarker for treatment of HCC.
着者Chan SL, Chan AWH, Yeo W
期刊名称EXPERT OPINION ON THERAPEUTIC TARGETS
出版年份20http://aims.cuhk.edu.hk/converis/portal/Publication/15
月份7
日期http://aims.cuhk.edu.hk/converis/portal/Publication/1
卷号http://aims.cuhk.edu.hk/converis/portal/Publication/19
期次7
出版社INFORMA HEALTHCARE
页次973 - 983
国际标準期刊号http://aims.cuhk.edu.hk/converis/portal/Publication/1472-8222
电子国际标準期刊号http://aims.cuhk.edu.hk/converis/portal/Publication/1744-763http://aims.cuhk.edu.hk/converis/portal/Publication/1
语言英式英语
关键词biomarker; drug; liver neoplasm; targeted therapy
Web of Science 学科类别Pharmacology & Pharmacy
